Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma

• Published in: British journal of cancer Vol. 113; no. 7; pp. 996 - 1002
• Main Authors: Rossi, L, Laas, E, Mallon, P, Vincent-Salomon, A, Guinebretiere, J-M, Lerebours, F, Rouzier, R, Pierga, J-Y, Reyal, F
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 29.09.2015; Nature Publishing Group
• Subjects: 692/699/67/1347; 692/699/67/1857; 692/700/1750; Biomedical and Life Sciences; Biomedicine; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer Research; Clinical Study; Drug Resistance; Epidemiology; Female; Humans; Ki-67 Antigen - analysis; Mitotic Index; Molecular Medicine; Oncology; Prognosis; Receptor, ErbB-2 - metabolism; Receptors, Steroid - metabolism; Survival Analysis; treatment; breast cancer; proliferation; Ki67; mitotic index; prognosis

Background: Inconsistencies between mitotic index (MI) and Ki67 measures have been identified in many breast tumour samples. The aim of this study was to describe the prognosis of hormone receptor-positive (HR+) HER2− tumours having discrepant MI and Ki67. Methods: We included a cohort of breast can...